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Purpose: RNA methylation eraser FTO and writer METTL3 play important roles in human 
diseases by regulating gene expression. However, the potential of FTO and METTL3 as markers 
in renal clear cell carcinoma (CCRCC) is still unknown. The purpose of this study is to 
investigate differential expression of FTO and METTL3 in CCRCC vs. normal kidney tissues, 
the association of FTO and METTL3 expression and methylation with and their interaction of 
FTO and METTL3 expression in patient survival in CCRCC.   
Method: FTO and METTL3 expression and methylation, the clinicopathologic data were 
retrieved from a publicly accessed dataset of The Cancer Genome Atlas (TCGA) of 537 patients 
with primary CCRCC. Survival analysis was performed using Kaplan-Meier survival curve and 
multivariate cox regression model. Random-effects meta-analysis was applied to examine 
differential expression of FTO and METTL3 in CCRCC vs. normal kidney tissues.  
Results: Significant upregulation of FTO and METTL3 expression with 1.64 (95% CI: 1.43-
1.89) and 1.17 (95% CI: 1.02-1.35) folds, respectively, were observed in CCRCC vs. normal 
kidney tissues. Survival analysis showed that a superior survival was observed in both either 
high FTO expression or low methylation, and either low METTL3 expression or high 
methylation. The adjusted hazard ratios (HRs) were 0.67 (95% CI: 0.49-0.91, p=0.01) for high 
vs. low FTO expression, 2.17 (95% CI: 1.38-3.42, p=0.0008) for high vs. low FTO methylation, 
1.97 (95% CI: 1.45-2.68, p<0.0001) for high vs. low METTL3 expression, and  0.49 (95% CI: 
0.31-0.79, p=0.003) for high vs low METTL3 methylation, respectively. A significant interaction 
between FTO and METTL3 expression was observed in CCRCC patient survival (P=0.0328).  
Conclusion: FTO and METTL3 expression and methylation are potential prognostic and 
diagnostic markers in CCRCC. 
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RNA modification takes place in all living organisms and during this post-transcriptional 
process, RNA nucleotides are modified. Up until now, over 100 different types of RNA 
modifications have been identified, most of them occur in structured RNA such as tRNA and 
rRNA, and they can also take place in mRNA, small and long non-coding RNAs.(LncRNAs) 
[1]These RNA modifications are critical in modulating gene expression,[2] and consequently 
impacting many essential biological processes.[3]Loss of regulation for RNA modifications 
could cause relevant diseases.[4] 
 
N6-methyladenosine (m6A) refers to the RNA modification during which the adenosine at the 
nitrogen-6 position is methylated, and it is the most abundant modification in mRNAs and 
LncRNAs. m6A has been demonstrated to be associated with a series of fundamental cellular 
functions such as splicing,[5]stability,[6]translation,[7]circadian clock,[8]stem cell 
differentiation[9], and innate immune response.[10] The abnormal m6A level has been reported 
to link to diverse cancer types, such as leukemia, breast cancer, cervical cancer, 
glioblastoma.[11] 
 
m6A methylation is a dynamic and reversible modification through the orchestration of  a set of 
proteins “writers” (methyltransferase), “erasers” (demethylase) and “readers” (binding proteins). 
[12] METTL3 is a major member of N6-adenosine-methyltransferase, which is encoded by 
METTL3 gene on chromosome 14. The depletion of this enzyme results in significant reduction 
in m6A level in mRNAs. [13] METTL3 has been reported to be associated with the pluripotency 
and differentiation of embryonic stem cells (ESCs). [14] METTL3 has also been shown to 
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participate in many fundamental biological processes, such as formation of the hematopoietic 
system, T cell homeostasis, and neural stem cells differentiation. [14] It has been shown that the 
METTL3 depletion in human myeloid leukemia cells is associated with increased differentiation 
and apoptosis, which has been found to have delayed leukemia in experimental mice in vivo. 
[15] Hua-Bing Li and colleagues have used METTL3 knockout mice to demonstrate that the lack 
of METTL3 can affect the homeostasis and differentiation of T cell, and as a result, the T cells 
would stay in the naïve state and lose the ability to respond to various stimuli.[10] The 
upregulation of METTL3 has been found in many tumors, including liver cancer, breast cancer, 
colorectal cancer, prostate cancer, etc.[16] It has been found that METTL3 can facilitate the 
translation and expression of several critical oncogenes  such as EGFR and TAZ in human 
cancer cells, and hence can boost the growth and invasion of the cancer cells. The depletion of 
METTL3 was observed to be related to remarkable reduction in growth, invasion of cancer cells, 
and increased cell apoptosis has also been found. In contrast, the overexpression of METTL3 has 
totally opposite effects on cancer cells.[17] 
 
Fat mass and obesity-associated protein FTO is the first identified demethylase of m6A, which is 
encoded by the FTO gene on chromosome 16. It has been demonstrated that the depletion of 
FTO can result in the elevated level of m6A in mRNA, while the overexpression of FTO is 
associated with decreased m6A level in human cells. [18] FTO has been found to be involved in 
many physiological processes, such as transcriptome regulation and translation. [19] It has been 
reported that FTO can target pre-mRNAs and act as an mediator in the process of alternative 
splicing and 3’end processing. [5] At present, FTO is mostly considered to be associated with 
obesity. It has been reported that, FTO, as an eraser of m6A, influences fat metabolism and 
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mitochondrial content by regulating m6A level in liver cells. Decreased levels of m6A and 
mitochondrial content with increased triglyceride (TG) accumulation  have been observed along 
with the high expression of FTO.[20] Since obesity is a  risk factor for many cancers, the 
association between FTO and cancers has attracted more and more attention recently. 
Accumulated evidence has shown the overexpressed FTO in several cancers, such as AML, 
endometrial cancer and gastric cancer. [19] It has been demonstrated to act as an oncogene in 
several cancers, and FTO can also promote the growth and transformation of cancer cells.[19] 
 
Recently, it has been reported that the cross-talk among m6A writers, readers and erasers can 
modulate the growth and progression of cancers by controlling m6A level and gene expression in 
cancer cells.[21] Another critical finding about m6A modification is that it can cause a structural 
switch between double-stranded RNAs (dsRNA) and single-stranded RNAs (ssRNA) in the 
secondary structure of RNAs.[22] m6A RNA modification  inhibited the innate immune 
response because it could cause the decrease of dsRNA, which acts as a stimulus to the innate 
immunity.[23]Kidney cancer has been proven to be an immunogenic tumor and almost all kidney 
cancers are associated with dysfunctional immunity. [24]The essential role that Innate immunity 
has played in the development and progression of renal cell carcinoma has also been 
identified.[25] Thus in this study, we aimed to investigate the association between RNA 
methylation machinery FTO and METTL3 expression and their interaction, as well as their 
promoter DNA methylation, with patient survival in kidney renal clear cell carcinoma, and to 
further explore the correlations between both FTO and METTL3 and dsRNA and innate 
immunity-related genes. 
 4 
Materials and Methods 
Gene expression, methylation and clinicopathologic data 
A CCRCC dataset from The Cancer Genome Atlas (TCGA), which is available at TCGA 
provisional (www.cbioportal.org) was used. The upper quartile normalized RNA-Seq by 
Expectation Maximization (RNA Seq V2 RSEM) data for FTO expression, the data for FTO 
methylation (HM450), the data for dsRNA related factors expression (TLR3, TLR7, TLR8, 
DDX58, IFIH1, NLRP3), the data for innate immunity related factors expression (CD274, CD80, 
CD86, FCGR3A) of 537 patients were extracted. The clinicopathologic data was also retrieved 
and combined with the gene expression and methylation data. 
 
Differential expression of FTO and METTL3 in renal clear cell carcinoma vs. normal 
kidney tissues 
Gene expression dataset OncomineTM (www.oncomine.org) (ThermoFisher Scientific, MA, 
USA) was used to compare the differential expression of FTO/METTL3 in CCRCC vs. normal 
kidney tissues. The filters used for searching were Gene: FTO/METTL3, Analysis Type: Cancer 
vs. Normal Analysis, Cancer Type: Kidney Cancer, Data Type: mRNA and Sample Type: 
Clinical Specimen. Only renal clear cell carcinoma studies were included for the meta-analysis, 
other types of kidney cancer, for example, renal papillary cell carcinoma were all excluded from 
the analysis. Eight studies for FTO and seven studies for METTL3 were included in the final 
analysis. Random-effects Meta-analysis was performed to investigate the differences in 
FTO/METTL3 expression between CCRCC vs. normal kidney tissue. The fold-change values 
from raw data were first transformed into Log2 fold-change to perform the Meta-analysis. The 
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final Fold-change value was calculated by transforming the summarized Log2 fold change back 
using formula: summarized Fold-change = 2summarized log2 Fold-change. 
 
Statistical Analysis 
SAS version 9.4 (SAS Institute, Inc., NC, USA) and R version 3.5.1 were used to perform the 
statistical analysis. The overall survival time in months was calculated as the time from the first 
diagnosis of CCRCC to the occurrence of death or the last follow-up. Kaplan-Meier survival 
curve analysis (log-rank test) was first performed to test the association between the overall 
survival and either FTO or METTL3 expression and methylation, respectively. All the 537 
patients in the study were first divided into three groups based on the tertile distribution of the 
gene expression and methylation, respectively. Then the pairwise tests were used to determine 
which group is significantly different from one another for each variable. For the comparison 
that didn’t have a significant result, these two groups would be combined as one group, then 
comparing to the other group. At last, the patients have been categorized as High FTO group and 
Low FTO group based on the expression of FTO, High FTO Methylation group and Low FTO 
Methylation group based on the FTO methylation level, High METTL3 group and Low 
METTL3 group based on the expression of METTL3, and High METTL3 Methylation group 
and Low METTL3 Methylation group based on the METTL3 methylation level. The Kaplan-
Meier survival curves have been constructed based on the final grouping described above. Then 
the Multivariate Cox regression model was used to adjust for the potential confounders, 
backward elimination strategy was used to obtain the final model. Wald test was performed to 
test the interaction effect between gene FTO and gene METTL3. The HRs and 95% CI were 
estimated after adjusting for age and tumor stage. The Spearman correlation analysis was 
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performed to evaluate the correlation between the FTO/METTL3 expression and dsRNA related 
genes, and also for the correlation between FTO/METTL3 expression and innate immunity 
related genes. A p-value less than 0.05 was considered as significant. 
Results 
1. Clinicopathologic characteristics of CCRCC patients 
The characteristics of the 537 patients with primary Renal Clear Cell Carcinoma (CCRCC) are 
shown in table 1. The average age for the patients in this study was 61-years old with a range 
from 25 to 90-years old. There were 64.4% male and 35.6% female in this study. Among the 530 
patients whose race information was available, the majority of them were Caucasian (87.9%), 
followed by African American (10.6%), and Asian (1.5%). The information for tumor stage was 
known for 534 patients and 50.4% of them had stage I tumor, followed by stage III (23.4%), 
stage IV (15.5%), and stage II (10.7%). During the follow-up, 33.0% of the CCRCC patients 
deceased, with an average overall survival time of 44.3 months, ranging from 0 to 149.1 months. 
Table 1. Clinicopathologic Characteristics of CCRCC Patients 
Characteristic N %  
Race 530   
     Asian 8 1.5  
     Black or African American 56 10.6  
     White 466 88.0  
Sex 537   
     Male 346 64.4  
     Female 191 35.6  
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Tumor Stage 534   
     Stage I  269 50.4  
     Stage II 57 10.7  
     Stage III 125 23.4  
     Stage IV 83 15.5  
Death 537   
     Yes 177 33.0  
     No 360 67.0  
        mean ± SD  Range 
     Age (years) 537 60.6±12.2   26-90 
 
2. Correlations for FTO expression vs. METTL3 expression, FTO expression vs. FTO 
methylation, METTL3 expression vs. METTL3 methylation 
The spearman correlation test was performed to test the correlations. The results showed that 
there was a significant negative correlation between the expression of FTO and METTL3 (p < 
0.0001), the correlation coefficient was -0.32, with a 95% CI of (-0.39, -0.24); There was a 
significant negative correlation between FTO expression and FTO methylation level (p < 
0.0001), the correlation coefficient was -0.42, with a 95% CI of (-0.51, -0.33); There was also a 
significant negative correlation between METTL3 expression and METTL3 methylation level (p 
< 0.0001), the correlation coefficient was -0.31, with a 95% CI of (-0.40, -0.20). The scatterplots 




Figure 1. Correlation between FTO Expression vs. METTL3 Expression 
 
 




Figure 3. Correlation between METTL3 Expression vs. METTL3 Methylation 
 
 
3. Association between FTO expression and overall patient survival in CCRCC 
The log-rank test showed a significant difference in overall survival time between patients with 
high or low FTO expression (log-rank p=0.003). The patients in high-level FTO group had a 
superior overall survival comparing to the patients in FTO low-level group. The Kaplan-Meier 
survival curves are shown in figure 4. 
 
To adjust for the potential confounders, the Multivariate Cox regression model was constructed, 
starting with the full model with all potential confounders (race, sex, tumor stage, age) available 
in the dataset, then used the backward elimination strategy to arrive at a parsimonious model. 
Three variables were retained in the final model (at p-value < 0.1), variable race and sex were 
finally dropped. The result is shown in table 2. After adjusting for tumor stage and age, the 
significant association between the FTO expression and death risk still remained. The high-level 
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FTO expression group decreased the risk of death comparing to the low-level group. (HR:0.67, 
95% CI: 0.49-0.91, p=0.01) 
Table 2. Association between FTO Expression and CCRCC Patient Survival 
Variable Death 
FTO  HR 95% CI  P  
Low Reference   
High 0.67 0.49-0.91 0.01 
Tumor Stage    
Stage I  Reference   
Stage II 1.21 0.65-2.24 0.553 
Stage III 2.38 1.59-3.58 <0.0001 
Stage IV 6.75 4.60-9.89 <0.0001 











Figure 4. Kaplan-Meier Survival Curves by FTO Expression 
 
 
4. Association between FTO Methylation level and overall patient survival in CCRCC 
The log-rank test was performed to test if there was any difference in patient survival between 
the two groups of patients with different levels of FTO methylation. It turned out that there was a 
borderline significant difference between the two groups (log rank p= 0.0682). Patients with 
Lower FTO methylation level seemed to have better overall survival comparing to those with 
higher FTO methylation level. The Kaplan-Meier survival curves constructed for these two 
groups have been shown in figure 5. 
 
In order to adjust for the potential confounders, the Multivariate Cox regression model was used, 
similar to the model for FTO expression, the construction of the model also started with all 
potential confounders inside (race, sex, tumor stage, age), and then backward elimination 
strategy was applied to arrive at the final parsimonious model. Two variables (race, sex) were 
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dropped during this process, and three variables were retained in the final model (at p-value 
<0.1). The results have been shown in table 3. After adjusting for tumor stage and age, there was 
a significant association between the FTO methylation level and the patient survival in CCRCC. 
The high-level FTO methylation group has relative elevated risk of death comparing to the low-
level group. (HR: 2.17, 95% CI: 1.38-3.42, p= 0.0008) 
 









Table 3. Association between FTO Methylation and CCRCC Patient Survival 
Variable Death 
FTO Methylation HR 95% CI  P  
Low Reference   
High 2.17 1.38-3.42 0.0008 
Tumor Stage    
Stage I  Reference   
Stage II 1.46 0.65-3.31 0.3607 
Stage III 3.21 1.84-5.62 <0.0001 
Stage IV 10.34 6.08-17.60 <0.0001 
Age 1.04 1.02-1.06 <0.0001 
 
5. Association between METTL3 expression and overall patient survival in CCRCC 
The log-rank test was performed for the two groups of patients based on the differentiated 
METTL3 expression level. The significant difference in patient survival has been observed 
between the two groups (p <0.0001), patients with higher METTL3 expression have inferior 
overall survival compared to those with lower METTL3 expression, which is opposite to the 
association between FTO expression and the overall survival. The Kaplan-Meier survival curves 
constructed for these two groups have been shown in figure 6. 
 
To adjust for the potential confounders, the Multivariate Cox regression model was applied, 
similar to the model for FTO expression, the construction of the model also started with all 
potential confounders inside (race, sex, tumor stage, age), and then the final parsimonious model 
 14 
was obtained using the backward elimination strategy. Two variables (race, sex) were dropped 
during this process, and three variables were retained in the final model (at p-value <0.1). The 
result has been shown in table 4. After adjusting for tumor stage and age, there was a significant 
association between the METTL3 expression level and the overall patient survival in CCRCC. 
The elevated METTL3 expression has raised the risk of death for the CCRCC patients. (HR: 
1.97, 95% CI: 1.45-2.68, p < 0.0001) 
 







Table 4. Association between METTL3 Expression and CCRCC patient survival 
Variable Death 
METTL3 HR 95% CI  P  
Low Reference   
High 1.97 1.45-2.68 < 0.0001 
Tumor Stage    
Stage I  Reference   
Stage II 1.20 0.65-2.22 0.5682 
Stage III 2.52 1.68-3.79 <0.0001 
Stage IV 7.05 4.81-10.32 <0.0001 
Age 1.03 1.02-1.05 <0.0001 
 
6. Association between METTL3 methylation level and overall patient survival in CCRCC 
The log-rank test was performed to test if there was any difference in patient survival between 
the two groups of patients with different levels of METTL3 methylation. Kaplan-Meier showed a 
significant difference between the two groups (log rank p=0.0004). Patients with high METTL3 
methylation level have superior overall survival comparing to those with low METTL3 
methylation level. The Kaplan-Meier survival curves constructed for these two groups have been 
shown in figure 7. 
 
In order to adjust for the potential confounders, the Multivariate Cox regression model was used, 
similar to the model for METTL3 expression, the construction of the model also started with all 
potential confounders inside (race, sex, tumor stage, age), and then backward elimination 
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strategy was applied to arrive at the final parsimonious model. Two variables (race, sex) were 
dropped during this process, and three variables were retained in the final model (at p-value 
<0.1). The result has been shown in table 5. After adjusting for tumor stage and age, there was a 
significant association between the METTL3 methylation level and patient survival in CCRCC. 
The high-level METTL3 methylation group has relative reduced risk of death comparing to the 
low-level group. (HR: 0.49, 95% CI: 0.31-0.79, p= 0.0008) 
 







Table 5. Association between METTL3 Methylation and CCRCC patient survival 
Variable Death 
Mettl3 Methylation HR 95% CI  P  
Low Reference   
High 0.49 0.31-0.79 0.0031 
Tumor Stage    
Stage I  Reference   
Stage II 1.44 0.64-3.26 0.379 
Stage III 2.59 1.47-4.55 0.001 
Stage IV 8.67 5.14-14.63 <0.0001 
Age 1.04 1.02-1.06 0.0003 
 
7. Effects of FTO-METTL3 Interaction on Patient Survival in CCRCC 
Wald test was performed to explore the interaction effect of FTO-METTL3 on patient survival in 
CCRCC. Patients have been divided into two groups based on the median distribution of FTO 
expression, and then also have been categorized into two groups based on the median 
distribution of the METTL3 expression. There were 266 patients in the Low FTO group, with the 
FTO expression ranging from 327.91 Reads Per Kilobase of transcript per Million mapped reads 
(RPKM) to 2349.60 RPKM, comparing to the 267 patients in the High FTO group, with the FTO 
expression ranging from 2350.79 RPKM to 6053.67 RPKM. For the two METTL3 groups, there 
were 266 patients in the Low METTL3 group, with the METTL3 expression ranging from 36.73 
RPKM to 437.52 RPKM, compared to the 267 patients in the High METTL3 group, with the 
METTL3 expression ranging from 438.51 RPKM to 1499.30 RPKM. The Wald test result has 
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shown a significant interaction between the FTO expression and METTL3 expression with the 
adjustment of age and tumor stage. (W2=4.5559, P=0.0328) The stratified result for FTO and 
METTL3 has been shown in table 6. 
Table 6. Stratified Hazard Ratios for FTO and METTL3 
Strata Death 
 HR 95% CI  
FTO High vs. Low at Low METTL3  1.15 0.71-1.88 
FTO High vs. Low at High METTL3 1.97 1.45-2.68 
 HR 95% CI 
METTL3 High vs. Low at Low FTO 2.19 1.38-3.50 
METTL3 High vs. Low at High FTO 1.10 0.71-1.70 
 
8. Correlation between FTO expression and dsRNA related genes 
Spearman Correlation results are shown in table 7. Significantly positive correlations were 
observed between FTO and TLR3, TLR7, TLR8, DDX58, IFIH1, NLRP3. (all p<0.0001) 
Correlation coefficients were 0.60 (95% CI: 0.54-0.65) for TLR3, 0.35 (95% CI: 0.27-0.42) for 
TLR7, 0.31 (95% CI: 0.23-0.38) for TLR8, 0.35 (95% CI:0.28-0.43) for DDX58, 0.40 (95% CI: 




Table 7. Spearman Correlation between FTO Expression and dsRNA Related Genes 
Gene N Correlation 
Coefficient 
95% CI  P  
TLR3 533 0.60 0.54-0.65 <0.0001 
TLR7 533 0.35 0.27-0.42 <0.0001 
TLR8 533 0.31 0.23-0.38 <0.0001 
DDX58 533 0.35 0.28-0.43 <0.0001 
IFIH1 533 0.40 0.32-0.47 <0.0001 
NLRP3 533 0.24 0.16-0.32 <0.0001 
 
9. Correlation between FTO expression and innate immunity related genes 
Spearman Correlation results are shown in table 8. Significantly positive correlations were 
observed between FTO and CD80, CD86, FCGR3A. Correlation coefficients were 0.10 (95% CI: 
0.02-0.19) for CD80 (p=0.0162), 0.17 (95% CI: 0.09-0.25) for CD86 (p<0.0001), 0.23 (95% CI: 
0.15-0.31) for FCGR3A (p<0.0001). While significantly negative correlations were observed 







Table 8. Spearman Correlation between FTO Expression and Innate Immunity Related Genes 
Gene N Correlation 
Coefficient 
95% CI P 
CD274 533 -0.09 -0.17, 0.00 0.0498 
CD80 533 0.10  0.02, 0.19 0.0162 
CD86 533 0.17  0.09, 0.25 <0.0001 
FCGR3A 533 0.23  0.15, 0.31 <0.0001 
 
10. Correlation between METTL3 expression and dsRNA related genes 
Spearman Correlation results are shown in table 9. Significantly negative correlations were 
observed between METTL3 and TLR3, TLR7, TLR8, DDX58, IFIH1, NLRP3. (all p<0.0001 
except for NLRP3 p=0.02) Correlation coefficients were -0.40 (95% CI: -0.46, -0.32) for TLR3, 
-0.28 (95% CI: -0.36, -0.20) for TLR7, -0.23 (95% CI: -0.31, -0.15) for TLR8, -0.25 (95% CI:-








Table 9. Spearman Correlation between METTL3 Expression and dsRNA Related Genes 
Gene N Correlation 
Coefficient 
95% CI  P  
TLR3 533 -0.40 -0.46, -0.32 <0.0001 
TLR7 533 -0.28 -0.36, -0.20 <0.0001 
TLR8 533 -0.23 -0.31, -0.15 <0.0001 
DDX58 533 -0.25 -0.33, -0.17 <0.0001 
IFIH1 533 -0.18 -0.26, -0.10 <0.0001 
NLRP3 533 -0.10 -0.18, -0.02 0.02 
 
11. Correlation between METTL3 expression and innate immunity related genes 
Spearman Correlation results are shown in table 10. Significantly negative correlations were only 
observed between METTL3 and CD86, FCGR3A. Correlation coefficients were -0.19 (95% CI: -
0.27, -0.11) for CD86 (p<0.0001), -0.20 (95% CI: -0.28, -0.12) for FCGR3A (p<0.0001). 
Table 10. Spearman Correlation between METTL3 Expression and Innate Immunity Related 
Genes 
Gene N Correlation 
Coefficient 
95% CI P 
CD274 533 0.04 -0.05,0.12 0.3749 
CD80 533 0.02 -0.06,0.11 0.6094 
CD86 533 -0.19 -0.27, -0.11 <0.0001 




12. Differential expression of FTO in CCRCC vs. normal kidney tissues 
The summary result of fold change in FTO expression in CCRCC comparing to normal kidney 
tissues from random effect Meta-analysis has been shown in table 11. Eight studies have met the 
including criteria described above in the method section, and fold-change, p-value, t-statistics, 
number of carcinoma samples, number of normal samples were extracted from these studies to 
perform the random-effects Meta-analysis. All of these eight studies have an upregulation of 
FTO expression in CCRCC comparing to that in normal kidney tissues, with fold-change greater 
than 1. the summary FTO expression from the random-effects Meta-analysis across these eight 
studies showed 1.64 folds upregulation in CCRCC compared to that in normal kidney tissues, 
with 95% CI ranging from 1.43 to 1.89. The forest plot has been shown in Figure 8. 




P-value t-statistics Ncase Nnormal 
Yusenko Renal      
Clear Cell Renal Cell Carcinoma vs. Normal 1.787 1.30E-06 5.884 26 5 
Jones Renal       
Clear Cell Renal Cell Carcinoma vs. Normal 2.235 9.06E-10 7.635 23 23 
Beroukhim Renal      
Non-Hereditary Clear Cell Renal Cell 
Carcinoma vs. Normal 
1.682 4.22E-06 
 
5.267 27 11 
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Hereditary Clear Cell Renal Cell Carcinoma 
vs. Normal 
1.688 6.08E-07 6.635 32 11 
Higgins Renal      
Clear Cell Renal Cell Carcinoma vs. Normal 1.659 0.116 1.623 24 3 
Lenburg Renal      
Clear Cell Renal Cell Carcinoma vs. Normal 1.694 0.005 3.031 9 9 
Cutcliffe Renal      
Clear Cell Sarcoma of the kidney vs. Normal 1.213 0.07 1.754 14 3 
Gumz Renal      
Clear Cell Renal Cell Carcinoma vs. Normal 1.263 0.089 1.436 10 10 
Summary Fold-change (95% CI) 1.64 (1.43, 1.89)    
 
Figure 8. Forest Plot for Random Effects Meta-analysis of Differential FTO Expression in CCRCC 
vs. Normal Kidney Tissues 
 
 
Overall Fold-change of FTO = 2
summarized log2 Fold-change 
= 1.64 (1.43 -1.89) 
 24 
13. Differential expression of METTL3 in CCRCC vs. normal kidney tissues 
The summary result of fold change in METTL3 expression in CCRCC comparing to normal 
kidney tissues from random effect Meta-analysis has been shown in table 12. Seven studies were 
included, and fold-change, p-value, t-statistics, number of carcinoma samples, number of normal 
samples were extracted from these studies to perform the random-effects Meta-analysis. All of 
these seven studies have an upregulation of METTL3 expression in CCRCC, comparing to that 
in normal kidney tissues, with fold-change greater than 1. The summary METTL3 expression 
from the random-effects meta-analysis across these seven studies showed 1.17 folds upregulation 
in CCRCC compared to that in normal kidney tissue, with 95% CI ranging from 1.02 to 1.35. 
The forest plot has been shown in Figure 9. 
Table 12. Random Effects Meta-analysis of Differential METTL3 Expression in CCRCC vs. 
Normal Kidney Tissues 
Study Fold-
change 
P-value t-statistics Ncase Nnormal 
Yusenko Renal      
Clear Cell Renal Cell Carcinoma vs. Normal 1.26 0.322 0.49 26 5 
Jones Renal       
Clear Cell Renal Cell Carcinoma vs. Normal 1.09 0.036 1.86 23 23 
Beroukhim Renal      
Non-Hereditary Clear Cell Renal Cell 
Carcinoma vs. Normal 
1.18 0.051 1.73 27 11 




2.77 32 11 
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Lenburg Renal      
Clear Cell Renal Cell Carcinoma vs. Normal 1.05 0.159 1.04 9 9 
Cutcliffe Renal      
Clear Cell Sarcoma of the kidney vs. 
Normal 
1.07 0.162 1.02 14 3 
Gumz Renal      
Clear Cell Renal Cell Carcinoma vs. Normal 2.22 0.003 3.18 10 10 
Summary Fold-change (95% CI) 1.17 (1.02, 1.35)    
 
Figure 9. Forest Plot for Random Effects Meta-analysis of Differential METTL3 Expression in 
CCRCC vs. Normal Kidney Tissues 
 
Discussion 
In this study, we demonstrated that patient survival in renal clear cell carcinoma (CCRCC) is 
associated with the FTO and METTL3 machinery. We found that patients with high FTO level 
have superior overall survival compared to those with low FTO level. The association remained 
Overall Fold-change of FTO = 2
summarized log2 Fold-change 
= 1.17 (1.02 -1.35) 
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significant after adjusting for age and tumor stage. This result suggests high FTO level has 
played a protective role during the prognosis of CCRCC patients. This effect has also been 
proven by the association between FTO methylation level and the patient survival in CCRCC. It 
has been shown that higher level of FTO methylation was associated with borderline 
significantly worse survival in CCRCC. After adjusting for the age and tumor stage, a significant 
difference was observed. A negative correlation has also been found between FTO level and 
FTO methylation level. All of the evidence above points to the fact that FTO is acting as an anti-
tumor factor in the CCRCC progression. 
 
Previous studies showed that FTO might play totally different roles in the progression and 
prognosis of different types of cancers. Xu D and colleagues found that among gastric cancer 
patients, highly expressed FTO is associated with poor survival and cancer occurrence.[26]While 
another study has found that FTO can act as a tumor inhibitor in CCRCC through a novel FTO‐
PGC‐1α signaling axis.[27]The reason for the distinct roles FTO has played in different cancers 
is still unclear, and the complicated mechanism under this dynamic process still needs further 
exploration.  
 
Since almost all kidney cancers are documented to be associated with immune dysfunction, 
[28]and recently, m6A modification has been demonstrated to be associated with the regulation 
of innate immune systems,[29] we tried to investigate the association between FTO and CCRCC 
patient survival from the immune level. 
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It has been found that m6A modification can cause a structural switch from double-stranded 
RNA (dsRNA) to single-stranded RNA in the secondary structure of RNA, [22]since dsRNA can 
trigger the activation of innate immunity,  the decreased amount of dsRNA resulting from this 
switch would result in downregulated response by innate immunity.[23] It has been proven by 
Katalin and colleagues that RNA with m6A modified will not activate toll-like receptors TLR3, 
TLR7, and TLR8, which are important TLR family members used to recognize pathogens by 
innate immune system. The m6A modification has been demonstrated to inhabit the activation of 
DCs. The secretion of cytokine and activation marker such as CD80, CD86 has been observed to 
be suppressed by m6A.[29]In this study, we found there was significantly positive correlation 
between FTO expression and TLR3, TLR7, TLR8, which is consistent with the findings from 
previous studies, since FTO acts as a demethylase in m6A, higher FTO expression is associated 
with lower m6A level, and as a result, more TLR receptors will be activated. Significantly 
positive correlation was also observed between FTO expression and CD80, CD86, which 
suggested that FTO can improve the activation and maturity of DCs. Instead, significantly 
negative correlation was observed between FTO expression and CD274(PD-L1), which 
suggested that higher FTO expression is associated with lower expression of checkpoint 
inhibitor. PD-L1 has been considered to act as suppressors for anti-tumor immune response and 
are critical in tumor progression, and it has been demonstrated to have reliable effects on treating 
many advanced cancers.[30] The significantly positive correlation was also observed between 
FTO and DDX58, IFIH1. These two genes encoded two essential innate immune receptors, RIG-
1 and MDA5, which also have been demonstrated as dsRNA detectors.[31] The result is 
consistent with the findings that m6A can switch the structure of secondary RNA from double-
stranded to single-stranded.  
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Based on all the evidence above, it is reasonable that high FTO level is associated with superior 
patient survival in CCRCC. Acting as eraser in m6A modification, FTO can remove the m6A 
from RNA, which will cause the increase in the amount of dsRNA, and as a stimulus for innate 
immunity, the immune response will be improved for CCRCC patients with high FTO level. 
 
On the opposite, since METTL3 acts as a methylase in m6A modification, it is expected that 
METTL3 will have an opposite effect on patient survival in CCRCC. The results from this study 
is exactly the same as expected. Patients with higher METTL3 expression are associated with 
inferior overall survival, the association remained significant after adjusting for age and tumor 
stage. The association between METTL3 methylation level and patient survival also have 
demonstrated that METTL3 acts as an unfavorable marker in the progression of CCRCC. The 
association remained significant after adjusting for age and tumor stage. A significantly negative 
correlation was also found between the METTL3 expression level and METTL3 methylation 
level. Based on all the evidence above, METTL3, on the opposite of FTO, is playing an 
offensive role in the progression of CCRCC. 
 
As opposite to FTO, significantly negative correlation was observed between METTL3 
expression and TLR3, TLR7, TLR8, DDX58, and IFIH1, which is consistent with the theory of 
RNA structure switch by m6A, and the activation of innate immunity as described above. Acting 
as the writer in m6A, high METTL3 level will produce more m6A modified RNA, coupled with 
diminished dsRNA, and result in less activation of dsRNA sensors and TLR receptors. There 
were also significantly negative correlations between METTL3 and CD80, FCGR3A, which 
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suggested inhibited innate immune response by METTL3. The result is supported by another 
study which has found the depletion of METTL3 can result in upregulated interferon related 
response and as a result, inhibit viruses infection.[32] However, no significant correlation was 
found between METTL3 level and anti-tumor immune inhibitor PD-L1. Since m6A is a dynamic 
process, and it has been demonstrated to be able to regulate gene expressions through various 
pathways, which are still not totally understood at present, further investigations of the 
complicated mechanisms are needed. 
 
Based on the opposite roles FTO and METTL3 played in the m6A modification process and also 
in CCRCC patient survival, at last, we also want to know whether there was an interaction 
between these two genes when they take effects on the prognosis of CCRCC. A study published 
last year has reported that the cross-talk among m6A writers, readers and erasers can regulate 
cancer growth and progression. They found that m6A methylase METTL14 and m6A 
demethylase ALKBH5 could regulate each other’s level and also suppress m6A reader YTHDF3 
to determine the m6A level in target genes. [33] Similarly, our study also found a significant 
interaction between FTO expression and METTL3 expression in CCRCC patient survival after 
adjusting for age and tumor stage. From the meta-analysis, both FTO and METTL3 have been 
shown upregulated in tumor in comparison with normal tissues, which suggested both of these 





In summary, this study has demonstrated that epigenetic silencing RNA methylation machinery 
FTO and METTL3 are associated with patient survival in CCRCC, they are also associated with 
innate immunity response level. This finding suggests that machinery FTO and METTL3 are 
potential prognostic and diagnostic markers for CCRCC, and further studies in how exactly this 
machinery regulates the immune gene expression are still needed in order to design target 
immunotherapy for CCRCC patients in the future. 
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